Updates

Ref: Akums/Exchange/2026-27/25 June 18, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Business Responsibility and Sustainability Report for the Financial Year 2025-26 Respected Sir/Ma’am, Pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Business Responsibility and Sustainability Report (‘BRSR’) of Akums Drugs and Pharmaceuticals Limited (“the Company”) for the Financial Year 2025-26, along with the Independent Assurance Statement on the BRSR, provided by BDO India Services Private Limited, which also forms part of the Integrated Annual Report for the Financial Year 2025-26. Integrated Annual Report with BRSR is also available on the website of the Company and can be accessed at https://www.akums.in/investors/annual-report/ This is for your information and records. Thanking you, For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl.: As above Akums Drugs Pharmaceuticals Limited Statutory Reports Manufacturing Excellence. Delivered Globally. 193 BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT ANNEXURE II SECTION A: GENERAL DISCLOSURES I. Details of the Listed Entity 1. Corporate Identity Number (CIN) of the Listed Entity L24239DL2004PLC125888 2. Name of the Listed Entity Akums Drugs and Pharmaceuticals Limited 3. Year of Incorporation 2004 4. Registered Office Address 304, 3rd Floor, Mohan Place, L.S.C, C-Block, Saraswati Vihar Delhi-110034 5. Corporate Address Akums House, Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi -110083 6. E-mail cs@akums.net 7. Telephone 011- 69041000 (Extn: 8676) 8. Website www.akums.in 9. Financial Year for which reporting is being done FY 2025-26 10. Name of the Stock Exchange(s) where shares are listed (I) BSE Limited (II) National Stock Exchange of India 11. Paid-up Capital ` 31,47,87,976 12. Name and contact details of the person to be contacted Dharamvir Malik, Company Secretary and Compliance Officer for BRSR queries (Telephone, Email) 13. Reporting Boundary – Standalone or Consolidated? Consolidated 14. Name of Assurance Provider BDO India Services Private Limited 15. Type of Assurance Obtained 1. Reasonable Assurance- Core Indicators 2. Limited Assurance- Essential (Other than Core Indicators) and Leadership Indicators II. Products / Services 16. Details of business activities (accounting for 90% of the turnover): S.No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1. Manufacturing of pharma products and CDMO 79.95% rendering of allied services API 4.23% Domestic Branded Formulations 10.25% International Branded Formulations 3.29% Trade Generics 2.29% stropeR yrotutatS 62-5202 tropeR launnA detargetnI Business Responsibility & Sustainability Report (Contd.) 17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover): S.No. Product / Service1 NIC Code % of Total Turnover contributed 1. Pharmaceutical formulations 2100 100% 1Considering "Pharmaceutical formulations" as a single product/service including testing, development and job work charges charged to customers. III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location No. of Plants No. of Offices Total National 14 5 19 International 0 0 0 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States) Pan India (28 states and 8 union territories) International (No. of Countries) 72 b. What is the contribution of exports as a percentage of the total turnover of the entity? 4.4% c. A brief on types of customers: Customer Segments and Market Reach Akums and its subsidiaries caters to a diversified customer base across the pharmaceutical value chain, enabling resilient revenue streams and fostering long-term partnerships: Pharmaceutical Companies: Akums and its subsidiaries collaborate with leading domestic pharmaceutical companies to provide end-to-end contract development and manufacturing services. These partnerships are built on a strong foundation of quality, scalability, and regulatory compliance, enabling clients to accelerate time-to-market and enhance product competitiveness. FMCG Companies: The Company also partners with FMCG and allied companies for the development and supply of nutraceutical products. These offerings are designed to address evolving consumer needs for preventive healthcare and nutritional well-being. Healthcare Providers: Akums serves physicians, hospitals, and pharmacists by ensuring a consistent supply of high-quality and affordable formulations. This contributes to improved patient outcomes and enhances access to essential healthcare solutions. Distribution Network: The Company leverages a robust pan-India distribution network, working closely with distributors and retail pharmacy chains to ensure extensive market reach and product availability across both urban and rural geographies. Akums Drugs Pharmaceuticals Limited Statutory Reports Manufacturing Excellence. Delivered Globally. 195 Business Responsibility & Sustainability Report (Contd.) Global Markets: Through its subsidiaries, including Akumentis Healthcare and Unosource Pharma, Akums has established a strong international presence, supplying branded and generic formulations to over 72 countries. The Company operates in alignment with diverse regulatory requirements across global markets. Government and Regulatory Interface: Akums maintains proactive engagement with government bodies and regulatory authorities, including institutions such as Indian Railways, Defence services, CGHS, Jan Aushadhi, BHEL, State Medical Corporations, CMSS, and HLL. These engagements support adherence to evolving regulatory frameworks, uphold quality standards, and contribute to national public health objectives. IV. Employees 20. Details as at the end of Financial Year: a. Employees and workers (including differently abled): - Sr. No. Particulars Total (A) Male Female No. (B) % (B/A) No. (C) % (C/A) Employees (including differently abled) 1. Permanent (D) 6,455 5,732 88.80% 723 11.20% 2. Other than permanent 0 0 0% 0 0% 3. Total employees (D+ E) 6,455 5,732 88.80% 723 11.20% Workers 4. Permanent (F) 882 850 96.37% 32 3.63% 5. Other than Permanent 10,673 7,103 66.55% 3,570 33.45% 6. Total workers (F + G) 11,555 7,953 68.83% 3,602 31.17% b. Differently abled Employees and workers: Sr. No. Particulars Total (A) No. (B) % (B/A) No. (C) % (C/A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 13 12 92.31% 1 7.69% 2. Other than permanent 0 0 0 0 0 3. Total employees (D+E) 13 12 92.31% 1 7.69% DIFFERENTLY ABLED WORKERS 4. Permanent (F) 3 3 100% 0 0% 5. Other than Permanent 15 14 93.33% 1 6.66% 6. Total workers (FG) 18 17 94.44% 1 5.55% stropeR yrotutatS 62-5202 tropeR launnA detargetnI Business Responsibility & Sustainability Report (Contd.) 21. Participation/Inclusion/Representation of women: Total (A) No. and percentages of females No. of Females (B) % (B/A) Board of Directors2&3 8 1 12.50% Key Management Personnel2 5 0 0 2Includes the Managing Director 3Includes Key Managerial Personnel 22. Turnover rate for permanent employees and workers (Disclose trend for the past 3 years): FY 2025-26 FY 2024-25 FY 2023-24 Male Female Total Male Female Total Male Female Total Permanent 31.18% 33.03% 31.38% 35.71% 48.55% 37.21% 60.38% 66.13% 61.05% Employees Permanent Workers 36.97% 57.14% 37.56% 25.92% 18.18% 25.76% 29.55% 33.33% 29.60% V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ve [Showing first 8,000 characters — download PDF for full document]